The Value of Protecting the 340B Program for Patients and Providers: A Perspective from the Field
For three decades, the 340B drug pricing program has enabled hospitals that serve high numbers of low-income patient populations to stretch scarce federal resources and provide more comprehensive care to their patients and communities. The program, which has enjoyed strong bipartisan support, does not cost taxpayers a dime. Instead, the program is subsidized by drug companies, which are required to sell certain outpatient drugs at a discount to eligible providers. These discounts help hospitals provide critical programs and services to their patients such as medication therapy management…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.